Taking the rebates that it expects to negotiate into consideration, Ultragenyx said that burosumab will cost approximately $160,000 per patient per year for children and $200,000 per patient per year for adults, depending on body weight. The company said that it does not plan to increase costs in the early years of the drug’s availability.
The FDA has approved Ultragenyx and Kyowa Hakko Kirin’s burosumab-twza (Crysvita) for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged 1 year or older.
XLH is a rare, hereditary, progressive, and lifelong skeletal disorder that is characterized by renal phosphate wasting caused by excess production of fibroblast growth factor 23 (FGF23), which suppresses active vitamin D production by the kidney. In children, XLH can cause rickets, delayed growth, and decreased height, and adults with XLH have an increased risk of fracture.
Burosumab, a recombinant, fully human monoclonal antibody, works by blocking FGF23, and can normalize phosphorous levels, improve bone mineralization, improve rickets in children, and promote fracture healing in adults.
The FDA approval for the pediatric population is supported by 64-week data from a study in 52 patients, aged 5 to 12 years, which showed improvement in patients’ rickets, increased serum phosphorous levels, decreased serum alkaline phosphatase activity, and increased growth. The indication is also supported by 40-week data from an open-label study in 13 patients aged 1 to 4 years.
The adult indication is supported by 24-week data in a randomized, double-blind, placebo-controlled study in 134 adults. Treatment with burosumab resulted in a higher proportion of patients achieving serum phosphorous levels above the lower limit of normal, and a higher rate of complete healing of active fractures, versus placebo. Data from a 48-week open-label study showed healing of ostomalacia.
Lead investigator Tom Carpenter, MD, director of the Yale Center for X-Linked Hypophosphatemia and professor of pediatric endocrinology at Yale University School of Medicine, called approval of the drug a “watershed moment” for patients with XLH, as it is the first drug that has the potential to correct renal phosphate wasting.
Ultragenyx told investors in a conference call that it is focused on providing access to the treatment for patients who need it. Burosumab will be available in 10-, 20-, and 30-mg vials; the 10-mg vial will cost $3400, and the larger vials will be priced linearly. The recommended dosage for children is 0.8 mg per kg, which will be administered once every 2 weeks. Adults will receive doses of 1 mg per kg, up to a maximum of 90 mg, every 4 weeks.
Taking the rebates that it expects to negotiate into consideration, Ultragenyx said that burosumab will cost approximately $160,000 per patient per year for children and $200,000 per patient per year for adults, depending on body weight. The company said that it does not plan to increase costs in the early years of the drug’s availability.
Steven B. Miller, MD, chief medical officer of pharmacy benefit manager (PBM) Express Scripts, told Forbes that “It’s not inexpensive, but I do believe the right word is responsible,” and added that the cost of the drug is “going to be a very reasonable tradeoff” considering the surgical interventions that patients currently require for XLH. By comparison, said Miller, other genetic diseases that cause similar levels of disability have treatments that cost $600,000 or more per year.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More